Talphera

409 articles about Talphera

• AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021

  8/9/2021

   AcelRx Pharmaceuticals, Inc. today announced that it will release second quarter financial results after market close on Monday, August 16, 2021 . AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time

• AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S.

  7/14/2021

  AcelRx to receive up to approximately $55 million in combined up-front and sales-based milestone payments for DZUVEO licensing agreement

• AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials

  6/17/2021

   AcelRx Pharmaceuticals, Inc. , today announced it has reached agreement with the Food and Drug Administration (FDA) with regards to finalizing corrective actions in a warning letter.

• Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting

  6/1/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced important findings from a podium presentation on DSUVIA

• Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting

  5/26/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming podium presentation on DSUVIA

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease

  5/20/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at Tampa General Hospital to evaluate the use of DSUVIA for patients with sickle cell disease presenting to the emergency department (ED) with painful vaso-occlusive crisis

• AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results

  5/17/2021

  AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, reported its first quarter 2021 financial results.

• Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting

  5/13/2021

  AcelRx Pharmaceuticals, Inc. announced a poster presentation at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of DSUVIA 30 mcg for the management of acute pain in an ambulatory surgery center.

• AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021

  5/10/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 17, 2021

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement

  5/6/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at The CORE Institute Specialty Hospital in Phoenix,

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure

  4/8/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at Montefiore Medical Center evaluating the perioperative use of DSUVIA

• AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

  3/31/2021

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors.

• AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings

  3/25/2021

   AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management

• AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference

  3/22/2021

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that management will present an overview of AcelRx Pharmaceuticals, followed by a fireside chat with Dr. Pamela Palmer

• AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  3/15/2021

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter

• AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021

  3/8/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures

  2/17/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study

• AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock

  1/20/2021

   AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen

  1/19/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), today announced an investigator-initiated study with University Hospitals (UH) Cleveland Medical Center that will evaluate the postoperative use of DSUVIA in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol.

• AcelRx Announces Underwritten Public Offering of Common Stock

  1/19/2021

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an underwritten public offering of its common stock.